Group 1 - The core product, Equil patch insulin pump, has received approval from the National Medical Products Administration for use in children and adolescents aged 3-17, expanding its market from adult diabetes patients to millions of domestic children and adolescents with diabetes [1][2] - The clinical trial for this indication was led by Zhejiang University School of Medicine Children's Hospital, in collaboration with six top children's hospitals in the country, demonstrating the effectiveness and safety of Continuous Subcutaneous Insulin Infusion (CSII) in treating diabetes in children and adolescents [1] - The patch insulin pump offers advantages over traditional tubing insulin pumps, including more precise and safe insulin delivery, convenience in wearing, cost-effectiveness, enhanced privacy, and elimination of issues like clogging and tubing entanglement [1] Group 2 - The expansion of the indication reflects the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management, further solidifying its leading position in the industry and strategically expanding the market space for its products [2] - The company will continue to focus on the global development of diabetes monitoring, treatment, and management methods, driving innovation in related technologies and products [2]
微泰医疗-B(02235)：贴敷式胰岛素泵儿童及青少年适应症获批